Gliatech Adcon
This article was originally published in The Gray Sheet
Executive Summary
Potential buyers of the firm's flagship anti-adhesion technology will have the option of finishing a 16-site pivotal trial to support gynecological and pelvic indications. The technology, including solution and gel formulation, is being auctioned as part of Gliatech's ongoing chapter 11 bankruptcy proceedings the firm filed in May (1"The Gray Sheet" May 6, 2002, p. 10). The Cleveland company had started a modular PMA submission for the pivotal trial indications, but the process was halted following receipt of a December 2000 application integrity policy (AIP) letter from FDA (2"The Gray Sheet" Jan. 1, 2001, p. 5). Gliatech claims it "has substantially completed its obligations" under the AIP and is "working toward the revocation of the company's AIP status." The firm has retained Adams, Harkness & Hill to manage the auction...
You may also be interested in...
Diagnostic Products Corp Is Second Device Firm Placed Under AIP In FY 2004
Diagnostic Products Corp says it will hire one or more third-party auditors to assist the firm in resolving an FDA application integrity policy (AIP)
Gliatech Adcon
All regulatory submissions related to the anti-adhesion technology over the next two years must be reviewed and certified by an independent auditor prior to submission to FDA under an agreement resolving issues raised in a December 2000 application integrity policy (AIP) letter from the agency. Gliatech plans to auction its Adcon assets as part of bankruptcy proceedings; the device is not available in the U.S. (1"The Gray Sheet" Sept. 30, 2002, In Brief)...
Gliatech Weighing Adcon Sale, Bankruptcy Filing; DoJ Makes Example Of Firm
Gliatech is considering the sale of its flagship Adcon anti-adhesion technology and filing for bankruptcy following a recent settlement with the Department of Justice due to failure to supply required information to FDA